View Older Stories View More Recent Stories
-
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap
-
Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("AR
-
Citius Pharmaceuticals to Present Corporate Update at Benzinga Global Small Cap Conference on December 8
-
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components
-
Citius Pharmaceuticals to Present at Virtual Fall Investor Summit
-
Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference
-
Citius Pharmaceuticals Issues October 2020 Letter to Shareholders
-
Citius Pharmaceuticals (CTXR) Signs Pact with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related ARDS
-
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acut
-
Citius's Mino-Lok trial sites resupplied with registration batch product
-
Citius Pharmaceuticals (CTXR) Reports Positive Results from Recent DMC Meeting for Mino-Lok Phase 3 Trial
-
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial
-
Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®
-
Citius Pharmaceuticals (CTXR) Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
-
Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
-
Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference
-
Citius Pharmaceuticals to Present at the LD 500 Virtual Conference
-
Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap
-
Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo
-
Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
-
Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
-
Citius Pharmaceuticals (CTXR) Announces $6 Million Bought Deal Offering of Common Stock
-
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
-
Citius Pharmaceuticals (CTXR) Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
-
Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
-
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
-
Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event
-
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
-
Citius Pharmaceuticals (CTXR) Regains Compliance with Nasdaq Listing Requirements
-
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
-
Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
-
Citius Pharmaceuticals (CTXR) Receives FDA Response on Pre-IND Application for its iMSCs to Treat ARDS in Patients with COVID-19
-
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVI
-
Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum
-
Citius Pharmaceuticals (CTXR) Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok Therapy
-
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
-
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
-
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Citius Pharmaceuticals (CTXR) Prices 7.058M Share Registered Direct Offering at $1.0625/Sh
-
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
Citius Pharmaceuticals Issues May 2020 Shareholder Letter
-
Citius Pharmaceuticals (CTXR) Reports Pre-IND Submission to FDA Under Coronavirus Treatment Acceleration Program for Novel Stem Cell Therapy for ARDS in COVID-19
-
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
-
Citius Pharmaceuticals (CTXR) Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS Associated with COVID-19
-
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
-
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
-
Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit
-
Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City
-
Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference
